|
Gene: KRIT1 |
Gene summary for KRIT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | KRIT1 | Gene ID | 889 |
Gene name | KRIT1 ankyrin repeat containing | |
Gene Alias | CAM | |
Cytomap | 7q21.2 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | O00522 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
889 | KRIT1 | P19T-E | Human | Esophagus | ESCC | 5.85e-04 | 4.22e-01 | 0.1662 |
889 | KRIT1 | P20T-E | Human | Esophagus | ESCC | 9.38e-55 | 1.22e+00 | 0.1124 |
889 | KRIT1 | P21T-E | Human | Esophagus | ESCC | 1.28e-41 | 7.75e-01 | 0.1617 |
889 | KRIT1 | P22T-E | Human | Esophagus | ESCC | 8.20e-31 | 5.12e-01 | 0.1236 |
889 | KRIT1 | P23T-E | Human | Esophagus | ESCC | 4.37e-34 | 8.70e-01 | 0.108 |
889 | KRIT1 | P24T-E | Human | Esophagus | ESCC | 4.62e-22 | 4.43e-01 | 0.1287 |
889 | KRIT1 | P26T-E | Human | Esophagus | ESCC | 3.07e-28 | 5.67e-01 | 0.1276 |
889 | KRIT1 | P27T-E | Human | Esophagus | ESCC | 2.16e-40 | 7.50e-01 | 0.1055 |
889 | KRIT1 | P28T-E | Human | Esophagus | ESCC | 9.95e-49 | 9.04e-01 | 0.1149 |
889 | KRIT1 | P30T-E | Human | Esophagus | ESCC | 5.24e-36 | 1.07e+00 | 0.137 |
889 | KRIT1 | P31T-E | Human | Esophagus | ESCC | 3.72e-28 | 4.30e-01 | 0.1251 |
889 | KRIT1 | P32T-E | Human | Esophagus | ESCC | 3.31e-27 | 4.88e-01 | 0.1666 |
889 | KRIT1 | P36T-E | Human | Esophagus | ESCC | 2.61e-22 | 6.28e-01 | 0.1187 |
889 | KRIT1 | P37T-E | Human | Esophagus | ESCC | 8.23e-34 | 6.30e-01 | 0.1371 |
889 | KRIT1 | P38T-E | Human | Esophagus | ESCC | 7.21e-08 | 3.31e-01 | 0.127 |
889 | KRIT1 | P39T-E | Human | Esophagus | ESCC | 5.59e-20 | 3.85e-01 | 0.0894 |
889 | KRIT1 | P40T-E | Human | Esophagus | ESCC | 1.04e-12 | 3.31e-01 | 0.109 |
889 | KRIT1 | P42T-E | Human | Esophagus | ESCC | 6.77e-31 | 7.68e-01 | 0.1175 |
889 | KRIT1 | P44T-E | Human | Esophagus | ESCC | 7.86e-09 | 3.18e-01 | 0.1096 |
889 | KRIT1 | P47T-E | Human | Esophagus | ESCC | 2.14e-41 | 7.60e-01 | 0.1067 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:003001018 | Esophagus | ESCC | establishment of cell polarity | 96/8552 | 143/18723 | 1.69e-07 | 2.67e-06 | 96 |
GO:004545419 | Esophagus | ESCC | cell redox homeostasis | 29/8552 | 35/18723 | 6.61e-06 | 6.75e-05 | 29 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
GO:19040197 | Esophagus | ESCC | epithelial cell apoptotic process | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
GO:00071636 | Liver | NAFLD | establishment or maintenance of cell polarity | 46/1882 | 218/18723 | 8.80e-07 | 4.60e-05 | 46 |
GO:00300106 | Liver | NAFLD | establishment of cell polarity | 34/1882 | 143/18723 | 1.41e-06 | 6.56e-05 | 34 |
GO:20001145 | Liver | NAFLD | regulation of establishment of cell polarity | 11/1882 | 22/18723 | 2.54e-06 | 1.06e-04 | 11 |
GO:00328784 | Liver | NAFLD | regulation of establishment or maintenance of cell polarity | 11/1882 | 25/18723 | 1.20e-05 | 3.69e-04 | 11 |
GO:1904019 | Liver | NAFLD | epithelial cell apoptotic process | 24/1882 | 121/18723 | 8.75e-04 | 1.07e-02 | 24 |
GO:1904036 | Liver | NAFLD | negative regulation of epithelial cell apoptotic process | 12/1882 | 50/18723 | 3.32e-03 | 2.93e-02 | 12 |
GO:00016676 | Liver | NAFLD | ameboidal-type cell migration | 65/1882 | 475/18723 | 6.32e-03 | 4.69e-02 | 65 |
GO:000716312 | Liver | Cirrhotic | establishment or maintenance of cell polarity | 82/4634 | 218/18723 | 1.55e-05 | 2.11e-04 | 82 |
GO:000166712 | Liver | Cirrhotic | ameboidal-type cell migration | 145/4634 | 475/18723 | 2.23e-03 | 1.36e-02 | 145 |
GO:200011411 | Liver | Cirrhotic | regulation of establishment of cell polarity | 12/4634 | 22/18723 | 2.61e-03 | 1.53e-02 | 12 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0452014 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
hsa0452015 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
hsa0452022 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
hsa0452032 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
hsa0452042 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0452052 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0452016 | Lung | IAC | Adherens junction | 37/1053 | 93/8465 | 1.99e-11 | 2.16e-09 | 1.43e-09 | 37 |
hsa0401510 | Lung | IAC | Rap1 signaling pathway | 41/1053 | 210/8465 | 2.01e-03 | 1.07e-02 | 7.10e-03 | 41 |
hsa0452017 | Lung | IAC | Adherens junction | 37/1053 | 93/8465 | 1.99e-11 | 2.16e-09 | 1.43e-09 | 37 |
hsa0401511 | Lung | IAC | Rap1 signaling pathway | 41/1053 | 210/8465 | 2.01e-03 | 1.07e-02 | 7.10e-03 | 41 |
hsa0452023 | Lung | AIS | Adherens junction | 34/961 | 93/8465 | 1.59e-10 | 1.29e-08 | 8.26e-09 | 34 |
hsa0401521 | Lung | AIS | Rap1 signaling pathway | 41/961 | 210/8465 | 3.23e-04 | 3.38e-03 | 2.16e-03 | 41 |
hsa0452033 | Lung | AIS | Adherens junction | 34/961 | 93/8465 | 1.59e-10 | 1.29e-08 | 8.26e-09 | 34 |
hsa0401531 | Lung | AIS | Rap1 signaling pathway | 41/961 | 210/8465 | 3.23e-04 | 3.38e-03 | 2.16e-03 | 41 |
hsa0452029 | Oral cavity | OSCC | Adherens junction | 62/3704 | 93/8465 | 6.34e-06 | 3.12e-05 | 1.59e-05 | 62 |
hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
hsa04520113 | Oral cavity | OSCC | Adherens junction | 62/3704 | 93/8465 | 6.34e-06 | 3.12e-05 | 1.59e-05 | 62 |
hsa0401519 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRIT1 | SNV | Missense_Mutation | novel | c.1277N>A | p.Arg426Lys | p.R426K | O00522 | protein_coding | tolerated(0.85) | possibly_damaging(0.867) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
KRIT1 | SNV | Missense_Mutation | c.816G>C | p.Gln272His | p.Q272H | O00522 | protein_coding | tolerated(0.38) | possibly_damaging(0.804) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
KRIT1 | SNV | Missense_Mutation | novel | c.1277G>T | p.Arg426Ile | p.R426I | O00522 | protein_coding | tolerated(0.06) | probably_damaging(0.974) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRIT1 | SNV | Missense_Mutation | c.1631N>T | p.Tyr544Phe | p.Y544F | O00522 | protein_coding | tolerated(0.21) | benign(0.007) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
KRIT1 | SNV | Missense_Mutation | c.2051G>A | p.Gly684Asp | p.G684D | O00522 | protein_coding | tolerated(0.26) | possibly_damaging(0.563) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KRIT1 | SNV | Missense_Mutation | rs747422648 | c.769G>A | p.Ala257Thr | p.A257T | O00522 | protein_coding | tolerated(0.45) | probably_damaging(0.98) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KRIT1 | SNV | Missense_Mutation | c.1145N>C | p.Arg382Thr | p.R382T | O00522 | protein_coding | tolerated(0.15) | probably_damaging(0.942) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
KRIT1 | SNV | Missense_Mutation | c.544N>G | p.Pro182Ala | p.P182A | O00522 | protein_coding | tolerated(0.83) | probably_damaging(0.98) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
KRIT1 | SNV | Missense_Mutation | c.629N>G | p.Tyr210Cys | p.Y210C | O00522 | protein_coding | tolerated(0.14) | probably_damaging(0.993) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
KRIT1 | insertion | Nonsense_Mutation | novel | c.6_7insTGAT | p.Asn3Ter | p.N3* | O00522 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |